An Act relative to prescription medication re-authorization
Generates a plain-language summary of the bill text and history.
| Date | Branch | Action |
|---|---|---|
| 6/17/2026 | House | Reporting date extended to Friday, July 31, 2026 |
| 3/19/2026 | House | Reporting date extended to Monday, June 15, 2026 |
| 12/8/2025 | House | Reporting date extended to Wednesday, March 18, 2026 |
| 9/18/2025 | House | Reported favorably by committee and referred to the committee on Health Care Financing |
| 6/3/2025 | Joint | Hearing scheduled for 06/10/2025 from 10:30 AM-01:00 PM in A-2 |
| 2/27/2025 | Senate | Senate concurred |
| 2/27/2025 | House | Referred to the committee on Financial Services |
No additional cosponsors.
| Committee | Recommendation | Vote |
|---|---|---|
| J11 | Favorable | 1 entries |
Notwithstanding any general or special law to the contrary, any licensed health insurer subject to the provisions of chapters 32A, 118E, 175, 176A, 176B or 176G of the General Laws shall not request or require annual re-authorizations for any prescription drug as defined in section 1 of chapter 94C of the General Laws that has been duly prescribed by a physician, physician’s assistant or nurse practitioner to treat any chronic disease including, but not limited to, diabetes, heart disease, Alzheimer's disease, cancer, stroke and respiratory disease
Notwithstanding any general or special law to the contrary, any licensed health insurer subject to the provisions of chapters 32A, 118E, 175, 176A, 176B or 176G of the General Laws shall not request or require annual re-authorizations for any prescription drug as defined in section 1 of chapter 94C of the General Laws that has been duly prescribed by a physician, physician’s assistant or nurse practitioner to treat any chronic disease including, but not limited to, diabetes, heart disease, Alzheimer's disease, cancer, stroke and respiratory disease